Group 1 - The acquisition of Jiatang by Tongrentang Group aims to create a complete closed-loop pharmaceutical industry chain covering herbal planting, drug production, terminal distribution, and medical services, but its effectiveness in alleviating the "private label" pain remains to be seen [1][7] - On February 3, Jiatang announced that its shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Tongrentang Group, transferring a total of 83.05 million shares for 1.461 billion yuan [3] - Following the transaction, Tongrentang Group will become the controlling shareholder of Jiatang with a 28.48% stake, and the actual controller will change to the State-owned Assets Supervision and Administration Commission of Beijing [3][4] Group 2 - Jiatang has faced financial pressure, with revenue figures from 2020 to 2024 showing a decline in net profit, particularly a drop to 161 million yuan in 2024, marking a ten-year low [5] - For the first three quarters of 2025, Jiatang reported a revenue of 14.46 billion yuan, a year-on-year decrease of 21.8%, and a net profit of 141 million yuan, down 38.81% year-on-year [6] - Tongrentang, founded in 1669, currently has multiple listed companies and is actively pursuing the listing of Tongrentang Medical and Health, which could enhance its capital presence [7] Group 3 - The merger is viewed as a "strong union," combining Tongrentang's brand strength and product resources with Jiatang's extensive distribution network, potentially allowing Jiatang to return to its core pharmaceutical operations [7] - Tongrentang has recently faced a trust crisis due to a product quality issue, which has negatively impacted its stock price and overall performance, with a revenue decline of 3.70% and a net profit drop of 12.78% in the first three quarters of 2025 [8]

嘉事堂药业股份有限公司 简式权益变动报告书 上市公司名称：嘉事堂药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：嘉事堂 股票代码：002462.SZ 信息披露义务人之一：中国光大实业（集团）有限责任公司 住所：北京市石景山区金府路 32 号院 3 号楼 9 层 915 室 通讯地址：北京市石景山区金府路 32 号院 3 号楼 9 层 915 室 信息披露义务人之二：中国光大医疗健康产业有限公司 住所：北京市石景山区金府路 32 号院 3 号楼 9 层 912 室 通讯地址：北京市石景山区金府路 32 号院 3 号楼 9 层 912 室 股份变动性质：协议转让（减少） 2026 年 2 月 声 明 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》及其它相关法律、法规和规范性文件的要求编写本报 告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购管理办法》《15 号准则》的规定，本报告书已全 面披露信息披露义务人在嘉事堂药业股份有限公司拥有权益的股份 ...

嘉事堂药业股份有限公司 详式权益变动报告书 上市公司名称：嘉事堂药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：嘉事堂 股票代码：002462.SZ 信息披露义务人：中国北京同仁堂（集团）有限责任公司 注册地址：北京市东城区东兴隆街 52 号 通讯地址：北京市东城区东兴隆街 52 号 股份变动性质：股份增加（协议转让） 签署日期：二〇二六年二月 1 信息披露义务人声明 四、本次权益变动尚需履行的决策及报批程序，包括但不限于：国有资产监 督管理部门审核批准、国家市场监督管理总局反垄断审查机构就本次交易涉及的 经营者集中事宜出具批准或同意或出具不予进一步审查决定以及深圳证券交易 所合规性确认。目前相关方正在推进相关审批程序。本次权益变动是否能通过相 关部门审批存在一定的不确定性，提请投资者注意相关风险。 五、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务 人和所聘请的专业机构外，没有委托或者授权任何其他人提供未在本报告书中列 载的信息和对本报告书作出任何解释或者说明。 六、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗 漏，并对其真实性、准确性、完整性承担个别和连带的法律责任 ...

中信证券股份有限公司 关于 嘉事堂药业股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二六年二月 声明 根据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券 的公司信息披露内容与格式准则第 15 号——权益变动报告书》及《公开发行证 券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》等法律法 规和规范性文件的规定，中信证券股份有限公司（以下简称"本财务顾问"）按照 行业公认的业务标准、道德规范，本着诚实信用、勤勉尽责的精神，对本次权益 变动的相关情况和资料进行了核查，对信息披露义务人出具的《嘉事堂药业股份 有限公司详式权益变动报告书》所披露的内容出具核查意见，以供投资者和有关 各方参考。 为此，本财务顾问特作出以下声明： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《嘉事堂药业股份有限公司详式权益变动报告书》进行了核查，确信披露文件内 容与格式符合规定，并有充分理由确信所发表的专业意见与信息披露义务人披露 的文件内容不存在实质性差异； 2、本财务顾问有充分理由确信本次权益变动符合相关法律、行政法规的规 定，有充分理由确信信息披露义务人 ...

Core Viewpoint - Jia Shitang (002462.SZ) is undergoing a change in control as its major shareholders, China Everbright Industrial Group and its subsidiary, are transferring their shares to Tongrentang Group, which will result in a new controlling shareholder and actual controller [1][2]. Group 1: Share Transfer Details - The share transfer involves a total of 83,057,236 shares, representing 28.48% of the company's total shares, being sold to Tongrentang Group at a price of RMB 17.59 per share, totaling approximately RMB 1.46 billion [2]. - Specifically, Everbright Health will receive approximately RMB 736.61 million, while Everbright Industrial will receive around RMB 724.37 million from the share transfer [2]. Group 2: Regulatory Approvals - The share transfer is subject to approval from the relevant state-owned assets supervision authority, antitrust review by the State Administration for Market Regulation, compliance confirmation by the Shenzhen Stock Exchange, and registration with the China Securities Depository and Clearing Corporation [2].

Core Viewpoint - The control of Jiasitang (002462) is set to change hands to Tongrentang Group following a share transfer agreement, marking a significant shift in the company's ownership structure and strategic direction [2][3]. Group 1: Company Overview - Jiasitang is a leading pharmaceutical commercial enterprise in Beijing, serving over 300 secondary and tertiary hospitals with a coverage rate of 99% [3]. - The company specializes in the distribution of pharmaceuticals and medical devices, as well as healthcare products and services, aiming to become a top-tier comprehensive service provider in the domestic pharmaceutical circulation and healthcare sector [2]. - Jiasitang has faced declining profitability, with net profits decreasing from 3.54 billion yuan in 2021 to an estimated 1.61 billion yuan in 2024 [3]. Group 2: Strategic Implications of the Acquisition - The acquisition by Tongrentang Group is seen as a strategic move to enhance Jiasitang's capabilities in the pharmaceutical commercial sector, filling gaps in distribution and channel management [5]. - This transaction is expected to create a "production + commercial" closed loop, which is crucial for addressing centralized procurement and medical insurance cost control [5]. - The integration of Jiasitang under Tongrentang Group is part of a broader initiative by the Beijing State-owned Assets Supervision and Administration Commission to optimize state capital layout and strengthen the influence of state-owned capital in key public health sectors [5].

Group 1 - Tong Ren Tang Group is expected to become the controlling shareholder of Jia Shi Tang [1][2] - On February 2, 2023, a share transfer agreement was signed, where Everbright Health and Everbright Industrial will transfer a total of 28.48% of Jia Shi Tang's shares to Tong Ren Tang Group at a price of 17.59 yuan per share, totaling 1.461 billion yuan [1][2] - Following this equity change, Tong Ren Tang Group will become the controlling shareholder of Jia Shi Tang, with the Beijing Municipal Government State-owned Assets Supervision and Administration Commission as the actual controller [2] Group 2 - Before the suspension, Jia Shi Tang's stock price was 16.4 yuan per share, with a market capitalization of 4.78 billion yuan [4] - Tong Ren Tang Group currently has three listed companies, including Tong Ren Tang in A-shares and Tong Ren Tang Technology and Tong Ren Tang Guo Yao in Hong Kong stocks [3]

Core Viewpoint - The transaction involves the transfer of 83.06 million shares of Jiatang (嘉事堂) from China Everbright Medical Health Industry Co., Ltd. and China Everbright Industrial Group Co., Ltd. to Beijing Tongrentang Group Co., Ltd., making Tongrentang the controlling shareholder with a 28.48% stake in Jiatang [3][4][8]. Group 1: Transaction Details - The share transfer price is set at 17.59 yuan per share, totaling 1.461 billion yuan [3][4]. - After the transaction, China Everbright Medical and China Everbright Industrial will no longer hold shares in Jiatang, while Tongrentang will become the controlling shareholder [4][8]. - The transaction is subject to several conditions, including internal approvals and regulatory approvals from state asset supervision authorities [5][9]. Group 2: Company Background - Tongrentang Group is a state-owned enterprise primarily engaged in the manufacturing and sales of traditional Chinese medicine and related products [4][9]. - Tongrentang has a rich history of over 350 years and includes subsidiaries such as Tongrentang Technology and Tongrentang Guoyao, focusing on modernizing traditional medicine and expanding into global markets [4][9]. - The transferring companies, China Everbright Medical and China Everbright Industrial, are subsidiaries of China Everbright Group, with operations in health consulting, medical research, and investment management [4][9].

证券日报网讯2月3日，嘉事堂（002462）在互动平台回答投资者提问时表示，截至2026年1月30日，公 司股东共2万8千余户。 ...

Group 1 - The core point of the article is the signing of a share transfer agreement between Everbright Industrial, Everbright Health, and Tongrentang Group, resulting in a change of the controlling shareholder of the company to Tongrentang Group [1] - Everbright Industrial and Everbright Health will transfer 41.1808 million shares and 41.8764 million shares, respectively, to Tongrentang Group [1] - Following the completion of this transaction, the actual controller of the company will change to the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality [1] Group 2 - The company's stock will resume trading on February 4, 2026, at the opening of the market [1]